Positive recommendation for saxagliptin

The DPP-4 inhibitor Onglyza® (saxagliptin), has received a positive recommendation from the All Wales Medicines Strategy Group (AWMSG) for use as part of a triple therapy treatment combination for type 2 diabetes within NHS Wales. Saxagliptin is recommended in adult type 2 diabetes patients aged 18 years and older, in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate blood glucose control.There are approximately 144,000 people with diagnosed type 2 diabetes in Wales and possibly a further 59,400 people who are undiagnosed. In Wales alone it is anticipated that 6,300 new